RIP2 knockdown inhibits cartilage degradation and oxidative stress in IL-1β-treated chondrocytes via regulating TRAF3 and inhibiting p38 MAPK pathway
- 26 September 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Immunology
- Vol. 232, 108868
- https://doi.org/10.1016/j.clim.2021.108868
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (51907197)
This publication has 45 references indexed in Scilit:
- RIP2 activity in inflammatory disease and implications for novel therapeuticsJournal of Leukocyte Biology, 2013
- Identification and characterization of receptor-interacting protein 2 as a TNFR-associated factor 3 binding partnerGene, 2013
- Signaling via the RIP2 Adaptor Protein in Central Nervous System-Infiltrating Dendritic Cells Promotes Inflammation and AutoimmunityImmunity, 2011
- Pomegranate extract inhibits the interleukin-1β-induced activation of MKK-3, p38α-MAPK and transcription factor RUNX-2 in human osteoarthritis chondrocytesArthritis Research & Therapy, 2010
- In vitro suppression of the MMP-3 gene in normal and cytokine-treated human chondrosarcoma using small interfering RNAJournal of Orthopaedic Surgery and Research, 2009
- NF-κB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanismJCI Insight, 2009
- Efficacy, pharmacodynamics, and safety of VX‐702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double‐blind, placebo‐controlled clinical studiesArthritis & Rheumatism, 2009
- The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2007
- Oxygen and reactive oxygen species in cartilage degradation: friends or foes?Osteoarthritis and Cartilage, 2005
- R-130823, a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis modelsEuropean Journal of Pharmacology, 2005